Anticancer therapy

Norenberg, Jeffrey P.

Title: Anticancer therapy

Abstract

A subject afflicted with a cancer or precancerous condition is treated by administering an agent that increases expression of somatostatin receptors, and a cytotoxic recognition ligand. In an alternative embodiment, somatostatin analogs, which are radiolabeled are used to treat cancer or precancerous conditions.

Inventors:: Norenberg, Jeffrey P.

Issue Date:: 2017-04-04

Research Org.:: STC.UNM, Albuquerque, NM (United States)

Sponsoring Org.:: USDOE

OSTI Identifier:: 1349739

Patent Number(s):: 9610371

Application Number:: 14/669,313

Assignee:: STC.UNM

Patent Classifications (CPCs):: A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61K - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES

Show more

A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61K - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
A61K2300/00 - Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
A61K31/7068 - having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K38/31 - Somatostatins
A61K45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K51/08 - Peptides, e.g. proteins {, carriers being peptides, polyamino acids, proteins}
A61K51/083 - {the peptide being octreotide or a somatostatin-receptor-binding peptide}
A61K51/088 - {conjugates with carriers being peptides, polyamino acids, proteins

Show less

DOE Contract Number:: FG01-001NE23554

Resource Type:: Patent

Resource Relation:: Patent File Date: 2015 Mar 26

Country of Publication:: United States

Language:: English

Subject:: 60 APPLIED LIFE SCIENCES; 59 BASIC BIOLOGICAL SCIENCES

Citation Formats


                    Norenberg, Jeffrey P. Anticancer therapy.  United States: N. p., 2017. 
        Web.

Copy to clipboard


                    Norenberg, Jeffrey P. Anticancer therapy.  United States.

Copy to clipboard


                    Norenberg, Jeffrey P. Tue .  
        "Anticancer therapy".  United States.  https://www.osti.gov/servlets/purl/1349739.

Copy to clipboard


                    
@article{osti_1349739,

  title        = {Anticancer therapy},

  author       = {Norenberg, Jeffrey P.},

  abstractNote = {A subject afflicted with a cancer or precancerous condition is treated by administering an agent that increases expression of somatostatin receptors, and a cytotoxic recognition ligand. In an alternative embodiment, somatostatin analogs, which are radiolabeled are used to treat cancer or precancerous conditions.},

  doi          = {},

  journal      = {},
number       = ,

  volume       = ,

  place        = {United States},

  year         = {2017},

  month        = {4}

}

Copy to clipboard

Patent:

Save / Share:

Export Metadata

Save to My Library

Works referenced in this record:

Treatment of damaged bone marrow and dosage units therefor
patent, July 1990

Borch, Richard F.; Schmalbach, Therese K.
US Patent Document 4,938,949
URL: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/4938949

Power-on reset circuit device for multi-level power supply sources
patent, May 1993

Nagai, Nobutaka
US Patent Document 5,214,316
URL: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5214316

Complexes of functionalized tetraazacyclododecane chelates with bismuth, lead, ytriium, actinium, or lanthanide metal ions
patent, June 1995

Gansow, Otto A.; Brechbiel, Martin W.; Magerstadt, Michael
US Patent Document 5,428,154
URL: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5428154

Multi-tyrosinated somatostatin analogs
patent, January 1997

Coy, David H.; Woltering, Eugene A.; O'Dorisio, M. Sue
US Patent Document 5,597,894
URL: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5597894

Peptides
patent, July 1997

Albert, Rainer; Macke, Helmut
US Patent Document 5,650,134
URL: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5650134

Cyclic peptide somatostatin analogs
patent, August 1999

Dean, Richard T.; McBride, William; Lister-James, John
US Patent Document 5,932,189
URL: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/5932189

Conformationally constrained backbone cyclized somatostatin analogs
patent, April 2000

Hornik, Vered; Gellerman, Gary; Afargan, Mich El M.
US Patent Document 6,051,554
URL: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6051554

Highly sensitive multimeric nucleic acid probes
patent, June 2000

Kool, Eric T.
US Patent Document 6,077,668
URL: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6077668

Somatostatin analogs for the treatment of cancer
patent, November 2001

Burman, Anand C.; Prasad, Sudhanand; Mukherjee, Rama
US Patent Document 6,316,414
URL: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6316414

Somatostatin analogs
patent, March 2002

Lister-James, John; Dean, Richard T.; Pearson, Daniel A.
US Patent Document 6,358,491
URL: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6358491

Conformationally constrained backbone cyclized somatostatin analogs
patent, August 2005

Hornik, Vered; Afargan, Michel; Gellerman, Gary
US Patent Document 6,930,088
URL: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/6930088

Peptide compounds having improved binding affinity to somatostatin receptors
patent, October 2006

Macke, Helmut; Reubi, Jean Claude; Schmitt, Jörg
US Patent Document 7,122,622
URL: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7122622

RGD (Arg-Gly-Asp) coupled to (neuro)peptides
patent, April 2007

DeJong, Marion; Krenning, Eric P.; Van Hagen, Petrus Martinus
US Patent Document 7,202,330
URL: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7202330

Nephrotoxicity in Mice After Repeated Imaging Using ¹¹¹In-Labeled Peptides
journal, May 2010

Melis, M.; Vegt, E.; Konijnenberg, M.
Journal of Nuclear Medicine, Vol. 51, Issue 6, p. 973-977
https://doi.org/10.2967/jnumed.109.074310

Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues
journal, November 2009

Rolleman, Edgar; Melis, Marleen; Valkema, Roelf
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 37, Issue 5, p. 1018-1031
https://doi.org/10.1007/s00259-009-1282-y

Tumor Imaging and Therapy Using Radiolabeled Somatostatin Analogues
journal, July 2009

de Jong, Marion; Breeman, Wout; Kwekkeboom, Dik
Accounts of Chemical Research, Vol. 42, Issue 7, p. 873-880
https://doi.org/10.1021/ar800188e

Long-term toxicity of [¹⁷⁷Lu-DOTA⁰,Tyr³]octreotate in rats
journal, September 2006

Rolleman, Edgar; Krenning, Eric; Bernard, Bert
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 34, Issue 2, p. 219-227
https://doi.org/10.1007/s00259-006-0232-1

Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings
journal, April 2002

de Jong, Marion; Valkema, Roelf; Jamar, Francois
Seminars in Nuclear Medicine, Vol. 32, Issue 2, p. 133-140
https://doi.org/10.1053/snuc.2002.31027

Phase I study of peptide receptor radionuclide therapy with [¹¹¹In-DTPA⁰]octreotide: The rotterdam experience
journal, April 2002

Valkema, Roelf; de Jong, Marion; Bakker, Willem H.
Seminars in Nuclear Medicine, Vol. 32, Issue 2, p. 110-122
https://doi.org/10.1053/snuc/2002.31025

Experimental facts supporting a red marrow uptake due to radiometal transchelation in ⁹⁰Y-DOTATOC therapy and relationship to the decrease of platelet counts
journal, February 2011

Walrand, Stephan; Barone, Raffaella; Pauwels, Stanislas
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 38, Issue 7, p. 1270-1280
https://doi.org/10.1007/s00259-011-1744-x

Phase I Trial of ⁹⁰Y-DOTATOC Therapy in Children and Young Adults with Refractory Solid Tumors That Express Somatostatin Receptors
journal, September 2010

Menda, Y.; O'Dorisio, M.; Kao, S.
Journal of Nuclear Medicine, Vol. 51, Issue 10, p. 1524-1531
https://doi.org/10.2967/jnumed.110.075226

Lymphocytic Toxicity in Patients After Peptide-Receptor Radionuclide Therapy (PRRT) with ¹⁷⁷Lu-DOTATATE and ⁹⁰Y-DOTATOC
journal, December 2009

Sierra, Maribel; Agazzi, Alberto; Bodei, Lisa
Cancer Biotherapy & Radiopharmaceuticals, Vol. 24, Issue 6, p. 659-665
https://doi.org/10.1089/cbr.2009.0641

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with ⁹⁰Y-DOTATOC and ¹⁷⁷Lu-DOTATATE: the role of associated risk factors
journal, April 2008

Bodei, Lisa; Cremonesi, Marta; Ferrari, Mahila
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 35, Issue 10, p. 1847-1856
https://doi.org/10.1007/s00259-008-0778-1

Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide
journal, January 2008

Barone, Raffaella; Walrand, Stéphan; Konijnenberg, Mark
Nuclear Medicine Communications, Vol. 29, Issue 3, p. 283-290
https://doi.org/10.1097/MNM.0b013e3282f3d03e

Treatment with ⁹⁰Y- and ¹⁷⁷Lu-DOTATOC in patients with metastatic neuroendocrine tumors
journal, December 2006

Frilling, Andrea; Weber, Frank; Saner, Fuat
Surgery, Vol. 140, Issue 6, p. 968-977
https://doi.org/10.1016/j.surg.2006.07.030

Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial
journal, September 2004

Pless, Miklos; Waldherr, Christian; Maecke, Helmut
Lung Cancer, Vol. 45, Issue 3, p. 365-371
https://doi.org/10.1016/j.lungcan.2004.02.020

Receptor Radionuclide Therapy with ⁹⁰Y-DOTATOC in Patients with Medullary Thyroid Carcinomas
journal, February 2004

Bodei, Lisa; Handkiewicz-Junak, Daria; Grana, Chiara
Cancer Biotherapy & Radiopharmaceuticals, Vol. 19, Issue 1, p. 65-71
https://doi.org/10.1089/108497804773391694

Assessment of Hepatic Toxicity from Treatment with ⁹⁰Y-SMT 487 (OctreoTher™) in Patients with Diffuse Somatostatin Receptor Positive Liver Metastases
journal, August 2003

Bushnell, David; Menda, Yusuf; Madsen, Mark
Cancer Biotherapy & Radiopharmaceuticals, Vol. 18, Issue 4, p. 581-588
https://doi.org/10.1089/108497803322287664

⁹⁰Y-DOTA-D-Phe¹-Try³- octreotide in therapy of neuroendocrine malignancies
journal, January 2002

Paganelli, G.; Bodei, L.; Handkiewicz Junak, D.
Biopolymers, Vol. 66, Issue 6, p. 393-398
https://doi.org/10.1002/bip.10349

The clinical value of [⁹⁰Y-DOTA]-D-Phe¹-Tyr³-octreotide (⁹⁰Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study
journal, July 2001

Waldherr, C.; Pless, M.; Maecke, H.
Annals of Oncology, Vol. 12, Issue 7, p. 941-945
https://doi.org/10.1023/A:1011160913619

Yttrium-90 DOTATOC: first clinical results
journal, October 1999

Otte, A.; Herrmann, R.; Heppeler, A.
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 26, Issue 11, p. 1439-1447
https://doi.org/10.1007/s002590050476

Similar Records in DOE Patents and OSTI.GOV collections:

Anticancer therapy

Patent Norenberg, Jeffrey P.

A subject afflicted with a cancer or precancerous condition is treated by administering an agent that increases expression of somatostatin receptors, and a cytotoxic recognition ligand. In an alternative embodiment, somatostatin analogs, which are radiolabeled are used to treat cancer or precancerous conditions.
Full Text Available
Method and system for administering internal radionuclide therapy (IRT) and external radiation therapy (XRT)

Patent Sgouros, George; Hobbs, Robert

A computerized method and system for determining an optimum amount of Internal Radionuclide Therapy (IRT) and External Radiation Therapy (XRT) to administer, comprising: obtaining activity image information for an imaged object from a detector; running a Monte Carlo simulation for the activity image information to obtain absorbed dose-rate image information at multiple times; adding the absorbed dose-rate image information from each time to obtain IRT total absorbed dose image information; and utilizing the IRT total dose image information to obtain total dose image information that is equivalent to XRT dose image information in terms of dose-rate, wherein the IRT dosemore » « less
Full Text Available
Proton beam therapy control system

Patent Baumann, Michael A; Beloussov, Alexandre V; Bakir, Julide; ...

A tiered communications architecture for managing network traffic in a distributed system. Communication between client or control computers and a plurality of hardware devices is administered by agent and monitor devices whose activities are coordinated to reduce the number of open channels or sockets. The communications architecture also improves the transparency and scalability of the distributed system by reducing network mapping dependence. The architecture is desirably implemented in a proton beam therapy system to provide flexible security policies which improve patent safety and facilitate system maintenance and development.
Full Text Available
Scanning systems for particle cancer therapy

Patent Trbojevic, Dejan

A particle beam to treat malignant tissue is delivered to a patient by a gantry. The gantry includes a plurality of small magnets sequentially arranged along a beam tube to transfer the particle beam with strong focusing and a small dispersion function, whereby a beam size is very small, allowing for the small magnet size. Magnets arranged along the beam tube uses combined function magnets where the magnetic field is a combination of a bending dipole field with a focusing or defocusing quadrupole field. A triplet set of combined function magnets defines the beam size at the patient. A scanningmore » « less
Full Text Available
Brain-specific enhancers for cell-based therapy

Patent Visel, Axel; Rubenstein, John L.R.; Chen, Ying-Jiun (Jasmine); ...

Herein are described a set of novel specific human enhancers for specific forebrain cell types used to study and select for human neural progenitor cells. This approach enables the ability to generate interneurons from human ES, iPS and iN cells, making them available for human transplantation and for molecular/cellular analyzes. These approaches are also directly applicable to generating other neuronal cell types, such as cortical and striatal projection neurons, which have implications for many human diseases.
Full Text Available

Similar Records

Title: Anticancer therapy

Abstract

Citation Formats

Treatment of damaged bone marrow and dosage units therefor patent, July 1990

Power-on reset circuit device for multi-level power supply sources patent, May 1993

Complexes of functionalized tetraazacyclododecane chelates with bismuth, lead, ytriium, actinium, or lanthanide metal ions patent, June 1995

Multi-tyrosinated somatostatin analogs patent, January 1997

Peptides patent, July 1997

Cyclic peptide somatostatin analogs patent, August 1999

Conformationally constrained backbone cyclized somatostatin analogs patent, April 2000

Highly sensitive multimeric nucleic acid probes patent, June 2000

Somatostatin analogs for the treatment of cancer patent, November 2001

Somatostatin analogs patent, March 2002

Conformationally constrained backbone cyclized somatostatin analogs patent, August 2005

Peptide compounds having improved binding affinity to somatostatin receptors patent, October 2006

RGD (Arg-Gly-Asp) coupled to (neuro)peptides patent, April 2007

Nephrotoxicity in Mice After Repeated Imaging Using 111In-Labeled Peptides journal, May 2010

Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues journal, November 2009

Tumor Imaging and Therapy Using Radiolabeled Somatostatin Analogues journal, July 2009

Long-term toxicity of [177Lu-DOTA0,Tyr3]octreotate in rats journal, September 2006

Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings journal, April 2002

Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experience journal, April 2002

Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts journal, February 2011

Phase I Trial of 90Y-DOTATOC Therapy in Children and Young Adults with Refractory Solid Tumors That Express Somatostatin Receptors journal, September 2010

Lymphocytic Toxicity in Patients After Peptide-Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC journal, December 2009

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors journal, April 2008

Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide journal, January 2008

Treatment with 90Y- and 177Lu-DOTATOC in patients with metastatic neuroendocrine tumors journal, December 2006

Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial journal, September 2004

Receptor Radionuclide Therapy with 90Y-DOTATOC in Patients with Medullary Thyroid Carcinomas journal, February 2004

Assessment of Hepatic Toxicity from Treatment with 90Y-SMT 487 (OctreoTher™) in Patients with Diffuse Somatostatin Receptor Positive Liver Metastases journal, August 2003

90Y-DOTA-D-Phe1-Try3- octreotide in therapy of neuroendocrine malignancies journal, January 2002

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study journal, July 2001

Yttrium-90 DOTATOC: first clinical results journal, October 1999

Treatment of damaged bone marrow and dosage units therefor
patent, July 1990

Power-on reset circuit device for multi-level power supply sources
patent, May 1993

Complexes of functionalized tetraazacyclododecane chelates with bismuth, lead, ytriium, actinium, or lanthanide metal ions
patent, June 1995

Multi-tyrosinated somatostatin analogs
patent, January 1997

Peptides
patent, July 1997

Cyclic peptide somatostatin analogs
patent, August 1999

Conformationally constrained backbone cyclized somatostatin analogs
patent, April 2000

Highly sensitive multimeric nucleic acid probes
patent, June 2000

Somatostatin analogs for the treatment of cancer
patent, November 2001

Somatostatin analogs
patent, March 2002

Conformationally constrained backbone cyclized somatostatin analogs
patent, August 2005

Peptide compounds having improved binding affinity to somatostatin receptors
patent, October 2006

RGD (Arg-Gly-Asp) coupled to (neuro)peptides
patent, April 2007

Nephrotoxicity in Mice After Repeated Imaging Using ¹¹¹In-Labeled Peptides
journal, May 2010

Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues
journal, November 2009

Tumor Imaging and Therapy Using Radiolabeled Somatostatin Analogues
journal, July 2009

Long-term toxicity of [¹⁷⁷Lu-DOTA⁰,Tyr³]octreotate in rats
journal, September 2006

Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings
journal, April 2002

Phase I study of peptide receptor radionuclide therapy with [¹¹¹In-DTPA⁰]octreotide: The rotterdam experience
journal, April 2002

Experimental facts supporting a red marrow uptake due to radiometal transchelation in ⁹⁰Y-DOTATOC therapy and relationship to the decrease of platelet counts
journal, February 2011

Phase I Trial of ⁹⁰Y-DOTATOC Therapy in Children and Young Adults with Refractory Solid Tumors That Express Somatostatin Receptors
journal, September 2010

Lymphocytic Toxicity in Patients After Peptide-Receptor Radionuclide Therapy (PRRT) with ¹⁷⁷Lu-DOTATATE and ⁹⁰Y-DOTATOC
journal, December 2009

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with ⁹⁰Y-DOTATOC and ¹⁷⁷Lu-DOTATATE: the role of associated risk factors
journal, April 2008

Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide
journal, January 2008

Treatment with ⁹⁰Y- and ¹⁷⁷Lu-DOTATOC in patients with metastatic neuroendocrine tumors
journal, December 2006

Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial
journal, September 2004

Receptor Radionuclide Therapy with ⁹⁰Y-DOTATOC in Patients with Medullary Thyroid Carcinomas
journal, February 2004

Assessment of Hepatic Toxicity from Treatment with ⁹⁰Y-SMT 487 (OctreoTher™) in Patients with Diffuse Somatostatin Receptor Positive Liver Metastases
journal, August 2003

⁹⁰Y-DOTA-D-Phe¹-Try³- octreotide in therapy of neuroendocrine malignancies
journal, January 2002

The clinical value of [⁹⁰Y-DOTA]-D-Phe¹-Tyr³-octreotide (⁹⁰Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study
journal, July 2001

Yttrium-90 DOTATOC: first clinical results
journal, October 1999